

Hypothalamic diseases with endocrine disturbances

Dr. Peter Igaz MD PhD

**2nd Department of Medicine
Faculty of Medicine
Semmelweis University**



Causes of hypothalamic dysfunction

- Tumors (astrocytoma, glioma, germinoma, craniopharyngeoma, large pituitary tumor, lymphoma)
- Haemorrhages
- Developmental abnormalities (arachnoideal cyst, holoprosencephaly)
- Granulomatous inflammation (histiocytosis X, sarcoidosis, TBC)
- inflammation (encephalitis, meningitis)
- Trauma
- Irradiation
- Hereditary diseases

Diseases of the hypothalamus

- Deficiency of trophormones (CRH, TRH, GnRH, GHRH) – growth failure, hypopituitarism, disorders of sexual development (isolated GnRH-deficiency – Kallmann-syndrome)
- Deficiency of posterior pituitary hormones
- Non-endocrine consequences of hypothalamic damage:
 - Feeding disorders (anorexia, hyperphagia, obesitas)
 - Disorders of fluid intake (adipsia, polydipsia)
 - Disorders of thermoregulation (hyperthermia, hypothermia)
 - Somnolentia, coma, lightmindedness
 - Mood lability

Kallmann syndrome

- Isolated GnRH deficiency.
- Migration defect of GnRH neurons from olfactory placod to hypothalamus.
- XR, AD or AR
- Secondary hypogonadism (low LH, FSH with low sex steroids) + anosmia/hyposmia
- MRI may show hypoplastic olfactory bulb
- Prevalence: 1:7500, more frequent in men

Hypothalamic forms of obesity


- Dystrophia adiposogenitalis (Fröhlich-syndrome)
 - obesity, hypogonadism, visual disturbances, skeletal malformations, white skin, intracranial tumor
- Laurence-Moon-Biedl syndrome (AR, 1:160.000)
 - Laurence-Moon: obesity, spastic paraparesis, retinitis pigmentosa, mental retardation, hypogonadism
 - Biedl-Bardet: polydactily, retinitis pigmentosa, mental retardation, hypogonadism, renal malformations
- Prader-Willi-Labhart syndrome

Prader-Willi-Labhart syndrome


GnRH deficiency, obesity, short stature, hypotony of the newborn, Diabetes mellitus type 1, strabismus, scoliosis, mental retardation.

Chemical structure of posterior pituitary hormones


A. Arginine Vasopressin



B. Oxytocin



C. Desmopressin



Some basic definitions

- **Polydipsia: exaggerated fluid intake**
- **Polyuria: increased urine**
- **Adipsia: loss of thirst sensing**

DIABETES INSIPIDUS

Major forms of diabetes insipidus

- **Central diabetes insipidus.**
- **Nephrogenic diabetes insipidus.**
- **Transitional diabetes insipidus in pregnancy (increased metabolism of ADH)**
- **„Primary polydipsia.” – primarily with psychiatric diseases – major problem in differential diagnosis.**

Major causes of centralis diabetes insipidus

- **Not a frequent disease, incidence: 4/100.000 person/year.**
- **Major causes:**
 - **Trauma**
 - **Neurosurgery (pituitary tumor)**
 - **Tumors of hypothalamus and pituitary**
 - **Rare inflammatory diseases (histiocytosis X, sarcoidosis)**
 - **Intracranial bleeding, Sheehan syndrome.**
 - **Very rare congenital forms.**

Major symptoms and diagnosis of diabetes insipidus

- Polyuria, variable, 18-20 liter/day in most severe cases.
- Polydipsia.
- Low urinary density (1001-1005 g/cm³) and urinary osmolality (<200 mosmol/kg).
- Thirst test: DI patients cannot concentrate urine even in case of lack of fluid intake – danger of exsiccosis.
- Oral water and salt test (20 ml/kg water and 0.9 % NaCl) on two consecutive days, in healthy individuals, diuresis after salt test is less than after water intake.
- Urine output decreases after desmopressin administration.

Treatment of central diabetes insipidus

- ADH is not stable for clinical use.
- ADH-analogue desmopressin, DDAVP as nasal spray, or tablets.
- Daily dose 1-2x 1 spray or 3x100-200 μg in tablets
- Other, very rarely used other drugs: chlorthalidone enhances the tubular action of ADH, carbamazepin stimulates endogenous ADH-secretion.

Nephrogenic diabetes insipidus

- **Disorder of renal ADH action.**
- **Two major forms:**
 - **Rare congenital (VP2 and AQP2 mutations)**
 - **Acquired (chronic renal diseases, metabolic disturbances /hypercalcaemia, hypokalaemia, gout/, osmotic diuretics /mannitol/, drugs /lithium, demeclocyclin, vincristin/)**
- **Treatment:**
 - **NSAID (indometacine, ibuprofen, aspirin) reduces polyuria, increases osmolality**
 - **Mild volumen depletion, tiazide diuretics in combination with NSAIDs are effective. K-sparing diuretics (amilorid) + tiazid also effective.**

SIADH

**Syndrome of inappropriate
secretion of antidiuretic
hormone.**

Major characteristics of paraneoplastic syndromes.

- Hormone secretion is rarely to be inhibited.**
- Mostly seen in advanced cancer diseases.**
- Hormones are not efficient as tumor markers.**
- Paraneoplastic endocrine syndromes are often caused by non-classic hormones, but similar mediators.**

Major hormones secreted by tumors

- Mediators inducing hypercalcaemia
 - Parathormon like peptide (PTHrP)
 - Vitamin D
 - Parathyroid hormone
- ADH
- ACTH
- IGF-II
- Others: GHRH, calcitonin, hCG, GH, CRH, erythropoetin, ANP, endothelin, renin, GI hormonok (GIP, somatostatin, PP, VIP etc.)

Diagnostic criteria of paraneoplastic endocrine syndromes

• Clinical criteria

- 1. hormone secretion is associated with the tumor
- 2. serum or urinary hormone concentrations are unusually high
- 3. hormone secretion cannot be inhibited
- 4. other cause is excluded
- 5. syndrome can be cured with tumor removal

• Research criteria

- 1. hormone or mRNA of peptide hormones are detected in tumor tissue
- 2. Hormone is secreted by cell cultures isolated from the tumor
- 3. A concentration gradient is measured between arterial and venous sides of the tumor.

SIADH

- **Probably the second most frequent paraneoplastic syndrome.**
- **ADH hypersecretion.**
- **Consequences:**
 - **Severe hyponatraemia (serum Na often <120 mmol/l).**
 - **Serum hypoosmolality (<275 mOsm/kg), urine is inappropriately concentrated (>100 mOsm/kg) and Na concentration is high.**
 - **Somnolence, coma, seizures in severe cases.**

Major causes of SIADH

- Tumors, paraneoplastic syndromes.
- CNS diseases (brain tumors, inflammations)
- Drugs (psychiatric medications /tricyclic antidepressants, phenothiazines)

Major tumors leading to SIADH

- **Small cell lung cancer (in 5-15% of patients SIADH can be observed)**
- **Other lung tumors.**
- **Carcinoids, prostate cancer., cervix cancer rarely, but many other tumors, as well.**

Diagnosis of SIADH

- **Hypoosmolar serum, and highly concentrated urine.**
- **Hyponatremia, high urinary Na-concentration.**
- **Lack of edemas.**
- **Other causes excluded: hypothyroidism, Addison-disease, hypopituitarism, drugs (psychiatric drugs, diuretics), CNS diseases.**

Treatment of SIADH

- **Severe case (se Na < 120 mmol/l)**
 - Hypertonic salt infusion
 - With or without loop diuretic
 - Target: 125 mmol/l
 - Speed of normalization cannot be higher than 0.5 mmol/l/h-t: danger of central pontine myelinolysis.
- **Milder case (se Na > 120 mmol/l)**
 - Fluid restriction (daily intake < 800-1000 ml)
 - Demeclocyclin inhibiting renal ADH action in chronic cases.

Effect of demeclocyclin of serum and urinary Na-concentration in a SIADH patient

